Drug Profile
Tuberculosis vaccine H56IC - AJ Vaccines
Alternative Names: Adjuvanted TB subunit vaccine H56IC - AJ Vaccines; AERAS-456; Ag85B-ESAT-6-Rv2660-IC31; H56; H56/IC31 vaccine; H56:IC31; H56IC; TB-vaccine-H56IC – AJ Vaccines; Tuberculosis vaccine H56IC - Statens Serum InstitutLatest Information Update: 27 Sep 2021
Price :
$50
*
At a glance
- Originator Statens Serum Institut
- Developer Aeras; AJ Vaccines
- Class Adjuvants; Recombinant fusion proteins; Subunit vaccines; Synthetic vaccines; Tuberculosis vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Tuberculosis
Most Recent Events
- 27 Sep 2021 Phase-II development is ongoing in Tuberculosis (prevention) in South Africa and Tanzania (IM) (NCT03512249)
- 31 Jan 2019 Phase-II clinical trials in Tuberculosis (Prevention) in South Africa, Tanzania (IM) (NCT03512249)
- 31 Jan 2019 Aeras initiates a phase II trial for Tuberculosis in South Africa (NCT03512249)